Numinus to research COMP360 psilocybin therapy in treatment-resistant depression as part of large phase 3 study Post published:May 30, 2023 Post category:Press Release
FILAMENT HEALTH ANNOUNCES INTERIM RESULTS FROM PHASE I CLINICAL TRIAL AT THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO Post published:May 30, 2023 Post category:Press Release
COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference Post published:May 27, 2023 Post category:Press Release
Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application. Post published:May 26, 2023 Post category:Press Release
Sunstone Therapies presents data at ASCO showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (MDD) Post published:May 26, 2023 Post category:Press Release
Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023 Post published:May 26, 2023 Post category:Press Release
Small Pharma Announces Significant Developments In Intellectual Property Portfolio Post published:May 25, 2023 Post category:Press Release
Numinus Aligns Business Initiatives to Prepare for Future Approval of MDMA-Assisted Therapy Post published:May 25, 2023 Post category:Press Release
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder Post published:May 22, 2023 Post category:Press Release
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification Post published:May 19, 2023 Post category:Press Release